Adamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Adamas Pharma (ADMS) Sees Red-to-Green Move
December 24, 2015 11:28 AM ESTAfter trading down as much as 8% earlier, yesterday's big mover Adamas Pharma (NASDAQ: ADMS) is back in positive territory.
... MoreAdamas Pharma (ADMS) Ramps Into the Close
December 23, 2015 3:38 PM ESTAdamas Pharma (NASDAQ: ADMS) ramps into the close. Shares are up 73.6% and near the highs after earlier announcing statistically significant ADS-5102 Phase 3 EASE LID data.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & Company
December 23, 2015 2:18 PM ESTNeedham & Company analyst Serge Belanger reiterated a Buy rating and raised his price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $38.00 (from $33.00) after the company reported positive top-line results from its first ph 3 study evaluating ADS-5102 in the treatment of levodopa-induced dyskinesia (LID) in Parkinson's... More
Aegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as Key
December 23, 2015 12:04 PM ESTAegis Capital reaffirmed its Buy rating and $29 price target on Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) after the company announced that its... More
Piper Jaffray Remains Bullish on Adamas Pharmaceuticals (ADMS)
December 23, 2015 9:12 AM ESTWhile no note was issued, Piper Jaffray's David Amsellem remains positive on Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) which is up over 30% premarket after its phase 3 trial for ADS-5102 (amantadine HCI) ER in Parkinson's (LID) meeting primary endpoint.
Adamas Pharma (ADMS) Announces Statistically Significant ADS-5102 Phase 3 EASE LID Data
December 23, 2015 6:20 AM ESTAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that its Phase 3 EASE LID clinical trial evaluating the companys investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinsons disease met its primary endpoint. Results from this randomized, placebo-controlled study showed a statistically significant reduction (p = 0.0009) in LID at 12 weeks for patients who received ADS-5102 versus placebo as assessed by the Unified Dyskinesia Rating Scale (UDysRS). This represents a 23 percent reduction in LID for ADS-5102-treated patients compared to placebo. The reduction in LID was maintained at 24 weeks (p =... More
